Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
67.1M
-
Shares change
-
+6.57M
-
Total reported value, excl. options
-
$2.7B
-
Value change
-
+$296M
-
Put/Call ratio
-
0.24
-
Number of buys
-
96
-
Number of sells
-
-57
-
Price
-
$40.20
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q1 2024
176 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q1 2024.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.1M shares
of 69.8M outstanding shares and own 96.15% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (6.33M shares), BAKER BROS. ADVISORS LP (6M shares), Atlas Venture Life Science Advisors, LLC (5.38M shares), BVF INC/IL (5.16M shares), VANGUARD GROUP INC (4.77M shares), FMR LLC (4.36M shares), WELLINGTON MANAGEMENT GROUP LLP (4.29M shares), Avoro Capital Advisors LLC (3.89M shares), BlackRock Inc. (3.66M shares), and Artal Group S.A. (3.03M shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.